Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial https://doi.org/10.1001/jama.2020.16349 Among 596 patients who were randomized, 584 began the study and received remdesivir or continued standard care (median… Continue reading "(22 Aug 2020) Remdesivir- No statistical significant difference compared to SOC"
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia https://doi.org/10.1371/journal.pone.0237831 Overall, 196 adults were included in the analyses. They were mainly male (67.4%), with comorbidities (78.1%) and severe COVID-19 pneumonia (83.7%). Median age was 67.9 years (range, 30-100) and median… Continue reading "(21 Aug 2020) Tocilizumab- early treatment with TCZ and methylprednisolone beneficial"
Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia https://doi.org/10.1101/2020.08.16.20175752 A cross-sectional study included 2,733 eligible patients subjected to MOH treatment protocol (hydroxychloroquine and zinc) and revisited the clinics within 3-7 days after treatment initiation. This… Continue reading "(17 Aug 2020) Hydroxychloroquine- proven safe in mild to moderate cases"
First report of tocilizumab use in a cohort of Latin American patients hospitalized for severe COVID-19 pneumonia https://doi.org/10.1101/2020.08.12.20173104 In an observational retrospective cohort study, hospitalized patients were evaluated by our multidisciplinary team for eventual use of tocilizumab. 29 patients received… Continue reading "(14 Aug 2020) Tocilizumab- found safe in patients with hyperinflammation"
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study https://doi.org/10.1371/journal.pone.0237693 In this retrospective observational cohort study (NCT04347993) drawn from electronic health records we sought to describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Patients… Continue reading "(14 Aug 2020) Hydroxychloroquine and Tocilizumab- HCQ shows no benefit, TCZ reduced mortality"
Efficacy of HCQ and TCZ in patients with COVID-19: A single-center retrospective chart review. https://doi.org/10.2196/21758 A retrospective cohort study was performed to determine the impact of HCQ and TCZ use on hard clinical outcomes during hospitalization. Independent t-test and multivariate… Continue reading "(14 Aug 2020) Hydroxychloroquine and tocilizumab- No significant reduction in in-hospital mortality"
Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID-19 https://doi.org/10.1002/jmv.26429 Seventy-four patients were included in each group. Seven-teen infections in the TCZ group (23%) and 6 (8%) infections in the control group occurred >48 hours after… Continue reading "(14 Aug 2020) Tocilizumab- post TCZ complications seen in 61% patients"
Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China. https://doi.org/10.1002/jmv.26193 In this descriptive observational study, we aimed to discuss the treatment response of HCQ in COVID-19 infected patients and 30 cases… Continue reading "(12 Aug 2020) Hydroxychloroquine- Early use better than later use"
Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin – A real world experience https://doi.org/10.1101/2020.08.05.20151027 This is a retrospective observational study to assess the effect of HCQ and Azithromycin on duration from symptom onset to… Continue reading "(11 Aug 2020) Hydroxychloroquine and Azithromycin-delayed SARS-CoV-2 virus clearance"
Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature https://doi.org/10.1101/2020.08.05.20169060 A retrospective study of patients admitted to the University of Washington Hospital system with COVID-19 and requiring supplemental oxygen was conducted.… Continue reading "(11 Aug 2020) Tocilizumab- associated with reduced CRP, fibrinogen, and temperature"
